Last reviewed · How we verify
MORF-057
At a glance
| Generic name | MORF-057 |
|---|---|
| Also known as | LY4268989 |
| Sponsor | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY4268989 (MORF-057) in Healthy Participants (PHASE1)
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (PHASE2)
- LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC (PHASE2)
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (PHASE2)
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (PHASE2)
- Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MORF-057 CI brief — competitive landscape report
- MORF-057 updates RSS · CI watch RSS
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) portfolio CI